07:43 AM EDT, 09/26/2024 (MT Newswires) -- Sage Therapeutics ( SAGE ) said Thursday that Biogen (BIIB) has terminated its rights under the partnership and license agreement with the company for the Sage-324 program, effective Feb. 17.

Sage said it will resume full ownership of the Sage-324 asset after termination.

The companies will continue to collaborate on Zurzuvae, a US Federal Drug Administration-approved treatment for women with postpartum depression, Sage said.

Biogen did not immediately respond to MT Newswires' request for comment.

Price: 6.95, Change: -0.07, Percent Change: -1.00